AUTHORS
wei bai, zhu chen2, ting zhang3, Qiubai Li, PhD4, Yingyong Xu, MD, PhD, MBA5, mucong Li6, chaojun hu7, liyin peng8, Jiuliang Zhao9, Jianxiang Wang Sr, MD, PhD10, Luhan Yang, PhD11, Mengtao Li12
AFFILIATIONS
1 Peking Union Medical College Hospital, beijing, China
2 The First Affiliated Hospital of USTC, hefei, China
3 The Second Affiliated Hospital of Zhejiang University, hangzhou, China
4 Union Hospital, Tongji Medical College, wuhan, China
5 Qihan Biotechnology, Hangzhou, China
6 Peking Union Medical College Hospital, beijing, China
7 Peking Union Medical College Hospital, beijing, China
8 Peking Union Medical College Hospital, beijing, China
9 Guizhou Provincial People's Hospital, guiyang, China, Peking Union Medical College Hospital, beijing, China
10 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
11 Qihan Biotechnology, Hangzhou, China
12 Peking Union Medical College Hospital, beijing, China
ABSTRACT
Background: Treatment options remain limited for patients with refractory systemic lupus erythematosus (SLE), particularly those with lupus nephritis (LN) or severe SLE-associated immune thrombocytopenia (SLE-ITP).. Autologous CD19 CAR-T has shown promise but is limited by manufacturing complexity and incomplete plasma cell elimination. We developed QT-019B, an allogeneic, off-the-shelf CD19/BCMA dual-target CAR-T designed for immediate availability and deep immune reset through concurrent depletion of B cells and plasma cells. QT-019B has received FDA Fast Track, RMAT, and BTD for refractory SLE-ITP.
Methods: This phase I/IIa trial (NCT07444307) employed a 3+3 dose-escalation (Dose A: 1×106 cells/kg; Dose B: 3×106 cells/kg) followed by expansion at the recommended dose (RD). Patients with refractory SLE received a single infusion after lymphodepletion. Endpoints included DLT, safety, CAR-T expansion, B-cell depletion, autoantibodies, and efficacy (SRI-4, LLDAS, CR).
Results: Enrollment was completed in July 2026. Twelve patients were treated: six in dose escalation (two SLE-LN and one SLE-ITP per cohort), followed by six SLE-ITP patients at 3×106 cells/kg (RD). No DLTs, ICANS, GVHD, or serious infections were observed; only two grade 1 CRS events were reported. Robust CAR-T expansion at RD. Complete B-cell aplasia was observed in all patients. All SLE-ITP patients (n=8) achieved rapid, durable CR with platelet normalization within 2 weeks, consistent with prior IIT data. Both SLE-LN patients at RD showed marked improvement, achieving SRI-4 and LLDAS by Month 2 with significant UPCR reduction. SRC selected 3×106 cells/kg as RD.
Conclusions: Allogeneic dual-target CD19/BCMA CAR-T QT-019B demonstrated a favorable safety profile and rapid, durable responses in refractory SLE-ITP and LN. These findings, together with FDA Fast Track, RMAT, and BTD for SLE-ITP, support progression to a confirmatory phase IIb trial.
DISCLOSURES
wei bai: No relevant conflicts of interest to declare.